Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized, Multicenter, Double-blind, Active Controlled Study to Compare the Efficacy and Safety of Two Different Anagrelide Formulations in Patients With Essential Thrombocythemia (TEAM-ET 2.0)

NCT02076815 is registered in ClinicalTrials.gov with AOP Orphan Pharmaceuticals AG as lead sponsor.

NCT NCT02076815
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02076815 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized, Multicenter, Double-blind, Active Controlled Study to Compare the Efficacy and Safety of Two Different Anagrelide Formulations in Patients With Essential Thrombocythemia (TEAM-ET 2.0)
Lead sponsor
AOP Orphan Pharmaceuticals AG
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2014
Completion date
April 30, 2015
Enrollment
106 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

essential thrombocythemia